This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Diagnosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The following patients should be investigated for strongyloidiasis:

  • travelers or people who migrate from an endemic area and develop the following within 3-4 weeks of travel:
    • persistent unexplained eosinophilia
      • should be investigated further in the first instance by repeating the test to confirm the result
      • other common causes (atopy, drugs) should be excluded by obtaining a carful history of the patient
      • present during the acute and chronic stages, but may be absent with dissemination (2)
    • gastrointestinal symptoms: nausea, vomiting, abdominal pain, bloating
    • pulmonary symptoms: fever, wheeze, persistent cough
    • cutaneous symptoms: larva currens, hives, or pustules

Further investigations carried out in patients include:

  • three stool samples for microscopy - collected on separate days
    • although the test has low sensitivity for detecting S stercoralis (around 50%) it is considered to be the gold standard for diagnosis
    • larvae usually appear in stools 3-4 weeks after dermal penetration.
  • blood test for S stercoralis serology
    • detects IgG to a filariform larval antigen

In patients with massive autoinfection the rhabditiform larvae are present in sputum and faeces.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.